Global Radiodermatitis Market is Likely to Grow at a CAGR Value of 3.90% By 2028

The global radiodermatitis market size was worth USD 521.30 million in 2021 and is estimated to grow to USD 655.81 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.9 percent over the forecast period. The report analyzes the radiodermatitis market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the radiodermatitis market.

Radiodermatitis is a severe side effect of ionizing radiation administered to the skin during cancer treatment and a result of nuclear attacks & disasters, like the one that happened in Fukushima in 2011. It is also known as radiation dermatitis, radiation-induced skin reactions, or radiation injury. More specifically, erythema, dry desquamation, and wet desquamation are the three types of radiodermatitis that 95 percent of cancer patients getting radiation therapy will experience. Numerous issues arise from these radiation skin reactions, including treatment delays, a decline in cosmetic appeal, and a decline in quality of life. Innovative treatment approaches and recent technological breakthroughs have only partially reduced these adverse side effects. Topical treatments such corticosteroids, hydrophilic creams, topical antibiotics, oral corticosteroids, analgesics, anti-inflammatory drugs, and dressings are typically used to treat radiodermatitis.

Over the forecast period, rising cancer rates are anticipated to fuel the expansion if global radiodermatitis market. For example, the American Cancer Society forecasts that there will be 606,880 deaths due to cancer and 1,762,450 new cancer cases in the USA in 2019. By more precisely targeting the tumor, contemporary radiotherapy treatments, including intensity-modulated radiation therapy (IMRT) and proton therapy, can reduce the risk for radiodermatitis. A situation like this is predicted to impede market expansion. In recent years, biotechnology and pharmaceutical industries have seen significant growth in Asian nations, including India, Japan, China, and Singapore, opening up new market potential.

The global radiodermatitis market is segregated based on product, distribution channel, and region. The market is divided into topical, oral drugs, and dressings based on product. Among these, the topical segment led the market in 2021 and is expected to maintain its dominance throughout the forecast period. Based on distribution channels, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the retail pharmacy category will dominate the global market.

The global radiodermatitis market is divided into geographic regions: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Due to the rising disposable income, rising healthcare spending, rising cancer patient prevalence, and rising adoption of cutting-edge healthcare products, Asia-Pacific is anticipated to lead the market throughout the analysis period. However, due to the inclusion of radiodermatitis products in healthcare reimbursement policies, there is an increase in the number of cancer patients, a rise in the demand for radiation therapy, and high healthcare spending, hence increasing the market growth.

Key players in the global radiodermatitis market include The 3M Company, Bayer Ag., Bausch Health Companies Inc., BMG Pharma S.P.A., Convatec Group PLC., Glaxosmithkline PLC, Helsinn Healthcare SA, Molnlycke Health Care AB, Mylan N.V., Stratpharma Ag, Smith & Nephew PLC.

Recent Development:

• September 2019: Integra LifeSciences Holdings Corporation purchased Rebound Therapeutics, a company that creates single-use medical tools for neurosurgery that allow for less invasive access.
• April 2019: To increase their focus on wound care for radiation therapy patients, CIVCO Radiotherapy and Stratpharma AG collaborated with CIVCO Radiotherapy, an expert in providing high-quality, patient-centric radioactive solutions. This is probably going to emphasize patient-centered treatment and enhance postoperative results.

Browse the full “Radiodermatitis Market By Product (Topicals, Oral Drugs & Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/radiodermatitis-market

The global Radiodermatitis Market is segmented as follows:

By Product

• Topical
• Oral Drugs
• Dressings

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com